Impact of occult bone marrow involvement on the outcome of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone therapy for diffuse large B-cell lymphoma

References

• Ziepert M, Hasenclever D, Kuhnt E, et al. Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20 + B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:2373–2380.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857–1861.
   PubMed Web of Science ®Google Scholar
• Ngo L, Hee SW, Lim LC, et al. Prognostic factors in patients with diffuse large B cell lymphoma: before and after the introduction of rituximab. Leuk Lymphoma 2008;49:462–469.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503–511.
   PubMed Web of Science ®Google Scholar
• Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8:68–74.
   PubMed Web of Science ®Google Scholar
• Fu K, Weisenburger DD, Choi WWL, et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and noCn-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol 2008;26:4587–4594.
   PubMed Web of Science ®Google Scholar
• Sehn LH. Early detection of patients with poor risk diffuse large B-cell lymphoma. Leuk Lymphoma 2009;50:1744–1747.
   PubMed Web of Science ®Google Scholar
• Campbell J, Seymour JF, Matthews J, et al. The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement. Eur J Haematol 2006;76:473–480.
   PubMed Web of Science ®Google Scholar
• Chung R, Lai R, Wei P, et al. Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic Index. Blood 2007;110:1278–1282.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Scott DW, Chhanabhai M, et al. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 2011;29:1452–1457.
   PubMed Web of Science ®Google Scholar
• Mitterbauer-Hohendanner G, Mannhalter C, Winkler K, et al. Prognostic significance of molecular staging by PCR-amplification of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma (DLBCL). Leukemia 2004;18:1102–1107.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999;17:1244–1257.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Talaulikar D, Dahlstrom JE, Shadbolt B, et al. Occult bone marrow involvement in patients with diffuse large B-cell lymphoma: results of a pilot study. Pathology 2007;39:580–585.
   PubMed Web of Science ®Google Scholar
• Yamamoto-Kawano C, Muroi K, Izumi T, et al. Clinical significance of flow cytometric evaluation of bone marrow involvement in B-cell lymphoma. Jichi Med Univ J 2006;29:105–113.
   Google Scholar
• Talaulikar D, Shadbolt B, Bell J, et al. Clinical role of flow cytometry in redefining bone marrow involvement in diffuse large B-cell lymphoma (DLBCL)--a new perspective. Histopathology 2008;52:340–347.
   PubMed Web of Science ®Google Scholar
• Talaulikar D, Shadbolt B, Dahlstrom JE, et al. Routine use of ancillary investigations in staging diffuse large B-cell lymphoma improves the International Prognostic Index (IPI). J Hematol Oncol 2009;22:49–57.
   Web of Science ®Google Scholar
• Coiffier B, Lepage E, Brière J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Wilkins BS. Lymphoma. In: Wickramasinghe SN, McCullough J, editors. Blood and bone marrow pathology. Philadelphia, PA: Churchill Livingstone; 2002. pp 405–436.
   Google Scholar
• Van Dongen J, Langerak A, Brüggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98–3936. Leukemia 2003;17:2257–2317.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.
   Web of Science ®Google Scholar
• Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163–170.
   PubMedGoogle Scholar
• Fleming TR, Harrington DP. Weighted logrank statistics. In: Fleming TR, Harrington DP, editors. Counting processes and survival analysis. Hoboken, NJ: John Wiley & Sons; 1991. pp 255–286.
   Google Scholar
• Machin D, Cambel M, Fayers P, et al. Comparing two survival curves. In: Machin D, Cambel M, Fayers P, et al., editors. Sample size tables for clinical studies. 2nd ed. Oxford, UK: Blackwell Science; 1997. pp 174–253.
   Google Scholar
• Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16:1141–1154.
   Web of Science ®Google Scholar
• Cox DR. Regression models and life-tables. J Roy Stat Soc B Stat Meth 1972;34:187–220.
   Web of Science ®Google Scholar
• Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496–509.
   Web of Science ®Google Scholar
• Harrell FE Jr, Califf RM, Pryor DB, et al. Evaluating the yield of medical tests. J Am Med Assoc 1982;247:2543–2546.
   PubMed Web of Science ®Google Scholar
• Morice WG, Kurtin PJ, Hodnefield JM, et al. Predictive value of blood and bone marrow flow cytometry in B-cell lymphoma classification: comparative analysis of flow cytometry and tissue biopsy in 252 patients. Mayo Clin Proc 2008;83:776–785.
   PubMed Web of Science ®Google Scholar
• Hanson CA, Kurtin PJ, Katzmann JA, et al. Immunophenotypic analysis of peripheral blood and bone marrow in the staging of B-cell malignant lymphoma. Blood 1999;94:3889–3896.
   PubMed Web of Science ®Google Scholar
• El-Sayed AM, El-Borai MH, Bahnassy AA, et al. Flow cytometric immunophenotyping (FCI) of lymphoma: correlation with histopathology and immunohistochemistry. Diagn Pathol 2008;3:43–55.
   PubMed Web of Science ®Google Scholar
• Morales AV, Arber DA, Seo K, et al. Evaluation of B-cell clonality using the BIOMED-2 PCR method effectively distinguishes cutaneous B-cell lymphoma from benign lymphoid infiltrates. Am J Dermatopathol 2008;30:425–430.
   PubMed Web of Science ®Google Scholar
• Dee J, Valdivieso M, Drewinko B. Comparison of the efficacies of closed trephine needle biopsy, aspirated paraffin-embedded clot section, and smear preparation in the diagnosis of bone-marrow involvement by lymphoma. Am J Pathol 1976;65:183–194.
   Web of Science ®Google Scholar
• Coller B, Chabner B, Gralnick H. Frequencies and patterns of bone marrow involvement in non-Hodgkin lymphomas: observations on the value of bilateral biopsies. Am J Hematol 1977;3:105–119.
   PubMed Web of Science ®Google Scholar
• Shimazaki C, Naba T, Nakagawa M. B-cell lymphoma-associated hemophagocytic syndrome. Leuk Lymphoma 2000;38:121–130.
   PubMed Web of Science ®Google Scholar
• Shimazaki C, Inaba T, Shimura K, et al. B-cell lymphoma associated with haemophagocytic syndrome: a clinical, immunological and cytogenetic study. Br J Haematol 2005;104:672–679.
   Web of Science ®Google Scholar
• Miyahara M, Sano M, Shibata K, et al. B-cell lymphoma-associated hemophagocytic syndrome: clinicopathological characteristics. Ann Hematol 2000;79:378–388.
   PubMed Web of Science ®Google Scholar
• Selleri C, Maciejewski JP, Sato T, et al. Interferon-gamma constitutively expressed in the stromal microenvironment of human marrow cultures mediates potent hematopoietic inhibition. Blood 1996;87:4149–4157.
   PubMed Web of Science ®Google Scholar
• Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004;103:3684–3688.
   PubMed Web of Science ®Google Scholar
• Thomson KJ, Morris EC, Bloor A, et al. Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. J Clin Oncol 2009;27:426–432.
   PubMed Web of Science ®Google Scholar
• Tierens AM, Holte H, Warsame A, et al. Low levels of monoclonal small B cells in the bone marrow of patients with diffuse large B-cell lymphoma of activated B-cell type but not of germinal center B-cell type. Haematologica 2010;95:1334–1341.
   PubMed Web of Science ®Google Scholar